Ae1 Ae3 Antibody Bafilomycin A1 Bile Acid Assay Bioassay Blog Ch 223191 Choline Acetyltransferase Antibody Ldn 193189 Medium Mip 1B peptide Polyclonal Purification Ru 58841 Trypsin Activity Assay Tubastatin A Uric Acid Assay Valproic Acid Sodium Salt Western Blot
Reconstitution of the destruction complex defines roles of AXIN polymers and APC in β-catenin capture, phosphorylation, and ubiquitylation
The Wnt/β-catenin pathway is a extremely conserved, incessantly mutated developmental and most cancers pathway. Its output is outlined primarily by β-catenin’s phosphorylation- and ubiquitylation-dependent proteasomal degradation, initiated by the multi-protein β-catenin destruction advanced.
The exact mechanisms underlying destruction advanced perform have remained unknown, largely due to the shortage of appropriate in vitro techniques. Right here we describe the in vitro reconstitution of an energetic human β-catenin destruction advanced from purified parts, recapitulating advanced meeting, β-catenin modification, and degradation.
We reveal that AXIN1 polymerization and APC promote β-catenin seize, phosphorylation, and ubiquitylation. APC facilitates β-catenin’s flux by the advanced by limiting ubiquitylation processivity and straight interacts with the SCFβ-TrCP E3 ligase advanced in a β-TrCP-dependent method.
Oncogenic APC truncation variants, though a part of the advanced, are functionally impaired. Nonetheless, even essentially the most severely truncated APC variant promotes β-catenin recruitment. These findings exemplify the ability of biochemical reconstitution to interrogate the molecular mechanisms of Wnt/β-catenin signaling.
A Community Pharmacology Strategy to Examine the Mechanism of Erjing Prescription in Sort 2 Diabetes
Erjing prescription (EJP) was an historical system that was recorded within the Normal Medical Assortment of Royal Benevolence of the Track Dynasty. It has been incessantly used to deal with sort 2 diabetes mellitus (T2DM) within the lengthy historical past of China.
The system consists of Lycium barbarum L. and Polygonatum sibiricum F. Delaroche with a ratio of 1 : 1. This examine aimed to establish the potential results and mechanisms of EJP remedy T2DM. The goal proteins and potential pathways of EJP in T2DM remedy have been investigated by the strategy of community pharmacology and real-time PCR (RT-PCR).
99 diabetes-related proteins have been regulated by 56 bioactive constituents in EJP in 26 sign pathways by Cytoscape dedication. In accordance with GO evaluation, 606 genes entries have been enriched. The PPI community prompt that AKT1, EGF, EGFR, MAPK1, and GSK3β proteins have been core genes. Among the many 26 sign pathways, the PI3K-AKT sign pathway was examined by the RT-PCR.
The expression stage of PI3K p85, AKT1, GSK3β, and Myc mRNA of this pathway was regulated by EJP. The examine based mostly on community pharmacology and RT-PCR evaluation revealed that the blood sugar stage was regulated by EJP by way of regulating the PI3K-AKT sign pathway. Loads of new remedy strategies for T2DM utilizing EJP have been supplied by community pharmacology evaluation.
Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
Acquired resistance to MAPK inhibitors limits the medical efficacy in melanoma remedy. We and others have lately proven that BRAF inhibitor (BRAFi)-resistant melanoma cells can develop a dependency on the therapeutic medication to which they’ve acquired resistance, making a vulnerability for these cells that may probably be exploited in most cancers remedy.
In drug-addicted melanoma cells, it was proven that this induction of cell loss of life was preceded by a particular ERK2-dependent phenotype change; nevertheless, the underlying molecular mechanisms are largely missing.
To extend the molecular understanding of this drug dependency, we utilized a mass spectrometry-based proteomic strategy on BRAFi-resistant BRAFMUT 451Lu cells, during which ERK1, ERK2, and JUNB have been silenced individually utilizing CRISPR-Cas9.
Inactivation of ERK2 and, to a lesser extent, JUNB prevents drug dependancy in these melanoma cells, whereas, conversely, knockout of ERK1 fails to reverse this phenotype, exhibiting a response much like that of management cells.
Our evaluation reveals that ERK2 and JUNB share comparable proteome responses dominated by reactivation of cell division. Importantly, we discover that EMT activation in drug-addicted melanoma cells upon drug withdrawal is affected by silencing ERK2 however not ERK1.
Furthermore, transcription issue (regulator) enrichment reveals that PIR acts as an effector of ERK2 and phosphoproteome evaluation reveals that silencing of ERK2 however not ERK1 results in amplification of GSK3 kinase exercise. Our outcomes depict potential mechanisms of drug dependancy in melanoma, which can present a information for therapeutic methods in drug-resistant melanoma.
Inhibition of AKT Signaling Alters βIV Spectrin Distribution on the AIS and Will increase Neuronal Excitability
The axon preliminary section (AIS) is a extremely regulated subcellular area required for neuronal firing. Adjustments within the AIS protein composition and distribution are a type of structural plasticity, which powerfully regulates neuronal exercise and will underlie a number of neuropsychiatric and neurodegenerative problems.
Regardless of its physiological and pathophysiological relevance, the signaling pathways mediating AIS protein distribution are nonetheless poorly studied. Right here, we used confocal imaging and whole-cell patch clamp electrophysiology in main hippocampal neurons to check how AIS protein composition and neuronal firing diversified in response to chose kinase inhibitors focusing on the AKT/GSK3 pathway, which has beforehand been proven to phosphorylate AIS proteins.
Picture-based options representing the mobile sample distribution of the voltage-gated Na+ (Nav) channel, ankyrin G, βIV spectrin, and the cell-adhesion molecule neurofascin have been analyzed, revealing βIV spectrin as essentially the most delicate AIS protein to AKT/GSK3 pathway inhibition.
Inside this pathway, inhibition of AKT by triciribine has the best impact on βIV spectrin localization to the AIS and its subcellular distribution inside neurons, a phenotype that Assist Vector Machine classification was in a position to precisely distinguish from management.
Therapy with triciribine additionally resulted in elevated excitability in main hippocampal neurons. Thus, perturbations to signaling mechanisms throughout the AKT pathway contribute to adjustments in βIV spectrin distribution and neuronal firing that could be related to neuropsychiatric and neurodegenerative problems.
Copper publicity induces hepatic G0/G1 cell-cycle arrest by suppressing the Ras/PI3K/Akt signaling pathway in mice
Copper (Cu), as a typical chemical contaminant in surroundings, is understood to be poisonous at excessive concentrations. The present analysis demonstrates the results of copper upon hepatocyte cell-cycle development (CCP) in mice. Institute of most cancers analysis (ICR) mice (n = 240) at an age of 4 weeks have been divided randomly into teams handled with totally different doses of Cu (0, 4, 8, and 16 mg/kg) for 21 and 42 days.
 GSK3B Antibody |
|||
| ABD6806 | Lifescience Market | 100 ug | EUR 525.6 |
GSK3B Antibody |
|||
| ABD7231 | Lifescience Market | 100 ug | EUR 525.6 |
 GSK3b antibody |
|||
| 70R-11869 | Fitzgerald | 100 ug | EUR 357 |
|
Description: Rabbit polyclonal GSK3b antibody |
|||
 GSK3B antibody |
|||
| 70R-15005 | Fitzgerald | 100 ul | EUR 497 |
|
Description: Rabbit polyclonal GSK3B antibody |
|||
GSK3B antibody |
|||
| 70R-17615 | Fitzgerald | 50 ul | EUR 289 |
|
Description: Rabbit polyclonal GSK3B antibody |
|||
GSK3B antibody |
|||
| 10R-1862 | Fitzgerald | 100 ul | EUR 468 |
|
Description: Mouse monoclonal GSK3B antibody |
|||
GSK3B Antibody |
|||
| 36918 | SAB | 100ul | EUR 319 |
GSK3B Antibody |
|||
| 36918-100ul | SAB | 100ul | EUR 302.4 |
GSK3B antibody |
|||
| 38353 | SAB | 100ul | EUR 439 |
GSK3B antibody |
|||
| 38353-100ul | SAB | 100ul | EUR 302.4 |
GSK3B antibody |
|||
| 38616 | SAB | 100ul | EUR 439 |
GSK3B antibody |
|||
| 38616-100ul | SAB | 100ul | EUR 302.4 |
GSK3B Antibody |
|||
| CSB-PA939628- | Cusabio | each | EUR 402 |
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
GSK3B Antibody |
|||
| CSB-PA939628-100ul | Cusabio | 100ul | EUR 379.2 |
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA080166 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC;WB:1:1000-2000.IHC:1:200-500 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA002848 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IP, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IP:2-5ug/mglysate.ELISA:1/20000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009038 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009963GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat, Pig. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009963LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:500 |
|||
GSK3B Antibody |
|||
| E036918 | EnoGene | 100μg/100μl | EUR 255 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| BF0695 | Affbiotech | 200ul | EUR 540 |
GSK3B Antibody |
|||
| BF0695-100ul | Affinity Biosciences | 100ul | EUR 210 |
|
Description: WB,IHC,IF/ICC,ELISA,FACS |
|||
GSK3B Antibody |
|||
| BF0695-200ul | Affinity Biosciences | 200ul | EUR 270 |
|
Description: WB,IHC,IF/ICC,ELISA,FACS |
|||
GSK3B Antibody |
|||
| BF0695-50ul | Affinity Biosciences | 50ul | EUR 150 |
|
Description: WB,IHC,IF/ICC,ELISA,FACS |
|||
GSK3B antibody |
|||
| CAF50144-100ug | Biomatik Corporation | 100ug | EUR 312 |
GSK3B Antibody |
|||
| E92081 | EnoGene | 100ul | EUR 255 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E93174 | EnoGene | 100ul | EUR 255 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E220184-1 | EnoGene | 50μg/50μl | EUR 145 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E220184-2 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E19-6806 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E19-7231 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E10-30006 | EnoGene | 100μg/100μl | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E10-30705 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| E10-30705T | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B antibody |
|||
| E39-03673 | EnoGene | 100ug/100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
GSK3B Antibody |
|||
| GWB-MT481D | GenWay Biotech | 50ug | Ask for price |
 GSK3b Antibody |
|||
| MBS5311338-01mg | MyBiosource | 0.1mg | EUR 490 |
GSK3b Antibody |
|||
| MBS5311338-5x01mg | MyBiosource | 5x0.1mg | EUR 2155 |
GSK3B Antibody |
|||
| MBS5313117-01mL | MyBiosource | 0.1mL | EUR 800 |
GSK3B Antibody |
|||
| MBS5313117-5x01mL | MyBiosource | 5x0.1mL | EUR 3440 |
GSK3B Antibody |
|||
| MBS2526368-006mL | MyBiosource | 0.06mL | EUR 180 |
GSK3B Antibody |
|||
| MBS2526368-012mL | MyBiosource | 0.12mL | EUR 260 |
GSK3B Antibody |
|||
| MBS2526368-02mL | MyBiosource | 0.2mL | EUR 405 |
GSK3B Antibody |
|||
| MBS2526368-5x02mL | MyBiosource | 5x0.2mL | EUR 1725 |
GSK3B Antibody |
|||
| MBS2526819-006mL | MyBiosource | 0.06mL | EUR 230 |
GSK3B Antibody |
|||
| MBS2526819-012mL | MyBiosource | 0.12mL | EUR 310 |
GSK3B Antibody |
|||
| MBS2526819-02mL | MyBiosource | 0.2mL | EUR 480 |
GSK3B Antibody |
|||
| MBS8526909-005mg | MyBiosource | 0.05mg | EUR 235 |
GSK3B Antibody |
|||
| MBS8526909-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3B Antibody |
|||
| MBS8526909-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GSK3B Antibody |
|||
| MBS8526909-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GSK3B Antibody |
|||
| MBS8526909-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GSK3B Antibody |
|||
| MBS7131863-01mL | MyBiosource | 0.1mL | EUR 270 |
GSK3B Antibody |
|||
| MBS7131863-5x01mL | MyBiosource | 5x0.1mL | EUR 1200 |
GSK3B Antibody |
|||
| MBS7136549-005mL | MyBiosource | 0.05mL | EUR 220 |
GSK3B Antibody |
|||
| MBS7136549-01mL | MyBiosource | 0.1mL | EUR 300 |
GSK3B Antibody |
|||
| MBS7136549-5x01mL | MyBiosource | 5x0.1mL | EUR 1350 |
GSK3B Antibody |
|||
| MBS7119532-005mg | MyBiosource | 0.05mg | EUR 150 |
GSK3B Antibody |
|||
| MBS7119532-01mg | MyBiosource | 0.1mg | EUR 190 |
GSK3B Antibody |
|||
| MBS7119532-5x01mg | MyBiosource | 5x0.1mg | EUR 845 |
GSK3B Antibody |
|||
| MBS7122537-005mg | MyBiosource | 0.05mg | EUR 150 |
GSK3B Antibody |
|||
| MBS7122537-01mg | MyBiosource | 0.1mg | EUR 190 |
GSK3B Antibody |
|||
| MBS7122537-5x01mg | MyBiosource | 5x0.1mg | EUR 845 |
GSK3B Antibody |
|||
| MBS7122623-005mg | MyBiosource | 0.05mg | EUR 150 |
GSK3B Antibody |
|||
| MBS7122623-01mg | MyBiosource | 0.1mg | EUR 190 |
GSK3B Antibody |
|||
| MBS7122623-5x01mg | MyBiosource | 5x0.1mg | EUR 845 |
GSK3B Antibody |
|||
| MBS8503766-01mL | MyBiosource | 0.1mL | EUR 325 |
GSK3B Antibody |
|||
| MBS8503766-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GSK3B Antibody |
|||
| MBS8503766-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GSK3B Antibody |
|||
| MBS8503766-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GSK3B Antibody |
|||
| MBS8503766-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GSK3B Antibody |
|||
| MBS8516276-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3B Antibody |
|||
| MBS8516276-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516276-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516276-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516276-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516665-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3B Antibody |
|||
| MBS8516665-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516665-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516665-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 465 |
GSK3B Antibody |
|||
| MBS8516665-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 465 |
GSK3B Antibody |
|||
| MBS8503474-01mL | MyBiosource | 0.1mL | EUR 325 |
GSK3B Antibody |
|||
| MBS8503474-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GSK3B Antibody |
|||
| MBS8503474-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GSK3B Antibody |
|||
| MBS8503474-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GSK3B Antibody |
|||
| MBS8503474-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GSK3B Antibody |
|||
| MBS850776-01mg | MyBiosource | 0.1mg | EUR 305 |
GSK3B Antibody |
|||
| MBS850776-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
GSK3B Antibody |
|||
| MBS850776-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
GSK3B Antibody |
|||
| MBS850776-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
GSK3B Antibody |
|||
| MBS850776-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
GSK3B antibody |
|||
| MBS831019-01mL | MyBiosource | 0.1mL | EUR 810 |
GSK3B antibody |
|||
| MBS831019-5x01mL | MyBiosource | 5x0.1mL | EUR 3505 |
GSK3B Antibody |
|||
| MBS9602821-005mL | MyBiosource | 0.05mL | EUR 260 |
GSK3B Antibody |
|||
| MBS9602821-01mL | MyBiosource | 0.1mL | EUR 325 |
GSK3B Antibody |
|||
| MBS9602821-02mL | MyBiosource | 0.2mL | EUR 400 |
GSK3B Antibody |
|||
| MBS9602821-5x02mL | MyBiosource | 5x0.2mL | EUR 1750 |
GSK3B Antibody |
|||
| MBS969826-005mg | MyBiosource | 0.05mg | EUR 190 |
GSK3B Antibody |
|||
| MBS969826-01mg | MyBiosource | 0.1mg | EUR 270 |
GSK3B Antibody |
|||
| MBS969826-5x01mg | MyBiosource | 5x0.1mg | EUR 1205 |
GSK3B Antibody |
|||
| MBS9411632-01mL | MyBiosource | 0.1mL | EUR 305 |
GSK3B Antibody |
|||
| MBS9411632-5x01mL | MyBiosource | 5x0.1mL | EUR 1230 |
GSK3B Antibody |
|||
| MBS9607870-01mL | MyBiosource | 0.1mL | EUR 260 |
GSK3B Antibody |
|||
| MBS9607870-02mL | MyBiosource | 0.2mL | EUR 305 |
GSK3B Antibody |
|||
| MBS9607870-5x02mL | MyBiosource | 5x0.2mL | EUR 1220 |
GSK3B antibody |
|||
| MBS9412683-005mL | MyBiosource | 0.05mL | EUR 300 |
GSK3B antibody |
|||
| MBS9412683-01mL | MyBiosource | 0.1mL | EUR 390 |
GSK3B antibody |
|||
| MBS9412683-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
GSK3B antibody |
|||
| MBS9410678-005mL | MyBiosource | 0.05mL | EUR 300 |
GSK3B antibody |
|||
| MBS9410678-01mL | MyBiosource | 0.1mL | EUR 390 |
GSK3B antibody |
|||
| MBS9410678-5x01mL | MyBiosource | 5x0.1mL | EUR 1610 |
 Rabbit Anti-Human GSK3B Polyclonal Antibody, Phospho-Tyr216 |
|||
| CPB-820RH | Creative Diagnostics | 100 ul | EUR 518.7 |
|
Description: Rabbit |
|||
 Antibody) Phospho-GSK3A/GSK3B (Y279/216) Antibody |
|||
| 1-CSB-PA000535 | Cusabio |
|
|
|
Description: A polyclonal antibody against Phospho-GSK3A/GSK3B (Y279/216). Recognizes Phospho-GSK3A/GSK3B (Y279/216) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000 |
|||
Phospho-GSK3A/GSK3B (Y279/216) Antibody |
|||
| MBS7121652-005mg | MyBiosource | 0.05mg | EUR 150 |
Phospho-GSK3A/GSK3B (Y279/216) Antibody |
|||
| MBS7121652-01mg | MyBiosource | 0.1mg | EUR 190 |
Phospho-GSK3A/GSK3B (Y279/216) Antibody |
|||
| MBS7121652-5x01mg | MyBiosource | 5x0.1mg | EUR 845 |
 GSK3A/GSK3B Antibody |
|||
| 1-CSB-PA002838 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3A/GSK3B. Recognizes GSK3A/GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000 |
|||
 GSK3A / GSK3B Antibody |
|||
| abx328487-100g | Abbexa | 100 µg | EUR 250 |
GSK3A / GSK3B Antibody |
|||
| 20-abx328487 | Abbexa |
|
|
GSK3A / GSK3B Antibody |
|||
| abx328487-50g | Abbexa | 50 µg | EUR 187.5 |
GSK3A/GSK3B Antibody |
|||
| MBS7122062-005mg | MyBiosource | 0.05mg | EUR 150 |
GSK3A/GSK3B Antibody |
|||
| MBS7122062-01mg | MyBiosource | 0.1mg | EUR 190 |
GSK3A/GSK3B Antibody |
|||
| MBS7122062-5x01mg | MyBiosource | 5x0.1mg | EUR 845 |
 Antibody) Phospho-GSK3A/GSK3B (Tyr279/216) Antibody |
|||
| CSB-PA575559- | Cusabio | each | EUR 402 |
|
Description: A polyclonal antibody against Phospho-GSK3A/GSK3B (Tyr279/216). Recognizes Phospho-GSK3A/GSK3B (Tyr279/216) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200 |
|||
Phospho-GSK3A/GSK3B (Tyr279/216) Antibody |
|||
| CSB-PA575559-100ul | Cusabio | 100ul | EUR 434.4 |
|
Description: A polyclonal antibody against Phospho-GSK3A/GSK3B (Tyr279/216). Recognizes Phospho-GSK3A/GSK3B (Tyr279/216) from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IHC, IF;WB:1:500-1:1000, IHC:1:50-1:100, IF:1:100-1:200 |
|||
Phospho-GSK3A/GSK3B (Tyr279/216) Antibody |
|||
| MBS7133572-01mL | MyBiosource | 0.1mL | EUR 310 |
Outcomes confirmed that top Cu publicity precipitated hepatocellular G0/G1 cell-cycle arrest (CCA) and lowered cell proportion within the G2/M part. G0/G1 CCA occurred with down-regulation (p < 0.05) of Ras, p-PI3K (Tyr458), p-Akt (Thr308), p-forkhead field O3 (FOXO3A) (Ser253), p-glycogen synthase kinase 3-β (GSK3-β) (Ser9), murine double minute 2 (MDM2) protein, and mRNA expression ranges, and up-regulation (p < 0.05) of PTEN, p-p53 (Ser15), p27, p21 protein, and mRNA expression ranges, which subsequently suppressed (p < 0.05) the protein and mRNA expression ranges of CDK2/Four and cyclin E/D. These outcomes point out that Cu publicity suppresses the Ras/PI3K/Akt signaling pathway to scale back the extent of CDK2/Four and cyclin E/D, that are important for the G1-S transition, and eventually causes hepatocytes G0/G1 CCA.
